We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-21.69%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
-$502M
Cap. Flow
-$120M
Cap. Flow %
-10.12%
Top 10 Hldgs %
72.7%
Holding
36
New
6
Increased
14
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$69M
2
CLDX icon
Celldex Therapeutics
CLDX
+$32.1M
3
VERA icon
Vera Therapeutics
VERA
+$30.3M
4
TYRA icon
Tyra Biosciences
TYRA
+$24.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$23.4M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$137M
2
DVAX
Dynavax Technologies
DVAX
+$52.1M
3
LQDA icon
Liquidia Corp
LQDA
+$23.8M
4
TSVT
2seventy bio
TSVT
+$17.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$165M 13.87%
1,167,570
-854,528
-42% -$137M
PCVX icon
2
Vaxcyte
PCVX
$7.89B
$121M 10.15%
3,200,000
+863,204
+37% +$69M
CLDX icon
3
Celldex Therapeutics
CLDX
$2.77B
$118M 9.91%
6,500,000
+1,435,793
+28% +$32.1M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.84B
$105M 8.79%
8,520,000
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.37B
$67M 5.63%
8,928,523
-156,845
-2% -$1.27M
CGON icon
6
CG Oncology
CGON
$6.11B
$64M 5.37%
2,611,662
+91,957
+4% +$2.59M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.13B
$63.4M 5.32%
4,700,000
+1,373,738
+41% +$23.4M
VERA icon
8
Vera Therapeutics
VERA
$2.54B
$57.6M 4.84%
2,400,000
+942,090
+65% +$30.3M
COGT icon
9
Cogent Biosciences
COGT
$6.79B
$54.5M 4.58%
9,105,000
– –
IMCR icon
10
Immunocore
IMCR
$1.78B
$50.3M 4.23%
1,695,576
+470,000
+38% +$14.1M
BEAM icon
11
Beam Therapeutics
BEAM
$2.58B
$49.2M 4.13%
2,518,170
+762,012
+43% +$20M
WVE icon
12
Wave Life Sciences
WVE
$1.12B
$39.6M 3.33%
4,899,497
– –
DVAX
13
DELISTED
Dynavax Technologies
DVAX
$34M 2.86%
2,620,797
-3,940,038
-60% -$52.1M
TVTX icon
14
Travere Therapeutics
TVTX
$5.33B
$32.3M 2.71%
1,802,750
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.82B
$22.4M 1.88%
2,406,067
+1,875,589
+354% +$24.3M
ENGN icon
16
enGene Therapeutics
ENGN
$122M
$22.4M 1.88%
4,994,090
– –
SLNO
17
CALL
DELISTED
Soleno Therapeutics
SLNO
$21.6M 1.82%
+302,500
New +$14.7M
LEGN icon
18
Legend Biotech
LEGN
$4.3B
$20.7M 1.74%
+610,000
New +$21.9M
CGEM icon
19
Cullinan Oncology
CGEM
$1.05B
$17.7M 1.49%
2,338,629
+1,085,891
+87% +$10.4M
NRIX icon
20
Nurix Therapeutics
NRIX
$2.43B
$9.5M 0.8%
+800,000
New +$13.4M
LQDA icon
21
Liquidia Corp
LQDA
$7.67B
$9.35M 0.79%
633,802
-1,632,526
-72% -$23.8M
IRWD icon
22
Ironwood Pharmaceuticals
IRWD
$611M
$8.56M 0.72%
5,822,938
+1,137,375
+24% +$2.71M
RLAY icon
23
Relay Therapeutics
RLAY
$4.02B
$8.03M 0.67%
3,063,292
+2,063,292
+206% +$8.08M
GERN icon
24
Geron
GERN
$911M
$5.82M 0.49%
+3,659,526
New +$8.91M
AMRN
25
Amarin Corp
AMRN
$284M
$5.56M 0.47%
620,731
– –
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Kynam Capital Management held 36 positions worth $1.19B, down 30% from $1.69B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kynam Capital Management withdrew a net $120M in Q1 2025, closing 4 positions and reducing 4 holdings. Its most notable exit was 2seventy bio, an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Legend Biotech worth $20.7M.

  • Kynam Capital Management's largest Q1 2025 buy was Legend Biotech: 610,000 shares worth $20.7M.
  • Kynam Capital Management added most to Vaxcyte in Q1 2025, an estimated $69M increase.
  • Kynam Capital Management's biggest Q1 2025 reduction was Natera, cutting an estimated $137M.
  • Kynam Capital Management fully exited 2seventy bio in Q1 2025, selling an estimated $17.5M.
  • Kynam Capital Management's ten largest holdings make up 73% of its $1.19B portfolio in Q1 2025.
  • Kynam Capital Management opened 6 new positions and closed 4 in Q1 2025.
  • Kynam Capital Management's portfolio value fell 30% quarter-over-quarter to $1.19B.

Based on Kynam Capital Management's 13F filing for Q1 2025, filed 15 May 2025.